Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

24 Sep 2007 08:00

ViaLogy PLC24 September 2007 24th September 2007Embargoed until: 0800hrs ViaLogy appoints Dr. Robert Dean as CEO ViaLogy PLC (VIY), the AIM-quoted technology company that is the leadinginnovator of network-centric, real time signal processing platforms for sensorapplications, today announces the appointment of Dr. Robert W Dean as Presidentand Chief Executive Officer (CEO) of ViaLogy LLC, its wholly-owned Americansubsidiary company based in Pasadena, California. Dr. Dean, who has served as anon-executive director on the ViaLogy PLC board since it joined AIM last year,will become an executive director on the main board. Dr. Dean moves to ViaLogy from the Science Applications InternationalCorporation (SAIC), a global systems and technical services company where he wasSenior Vice President, Corporate Market Development. Previously he has heldsenior management and board positions, concentrating on business development andstrategic planning, with such international organisations as Boeing, LockheedMartin, United Space Alliance, MacDonald Dettwiler, Electro Optic Systems, theRand Corporation and the Ball Corporation. During the President Reagan's term Dr. Dean served as Special Assistant to thePresident and was Senior Director of the National Security Council. He was alsothe senior White House executive responsible for high technology issues. Duringhis distinguished career he has held senior positions with the CentralIntelligence Agency and the US Department of State. He has received numerousawards for public service including the Grand Service Cross of the FederalRepublic of Germany, which is the highest civilian honour awarded to a foreigncitizen. "We are delighted that Bob Dean has agreed to accept the most senior managementposition with ViaLogy," said executive chairman, Terry Bond. "He has theexperience and vision that makes him the ideal person to lead us at thisexciting time in the company's development. Our technology has now beenvalidated for a number of important industrial applications. Next month,October, we will be announcing and demonstrating ViaLogy's commercial productsfor defence, oil and gas and enterprise management and business continuityapplications." Said Dr. Dean: "During the time I have served as a non-executive director ofViaLogy I have been very impressed by the potential of the company's technologyand products and the abilities of its staff. I look forward to growing the salesand marketing organisation and deploying ViaLogy products for partners andcustomers in the US and globally. "I am confident that ViaLogy will achieve the success in the market place thatits unique technology deserves." End For further information please contact: ViaLogyTerry Bond, Chairman +44 (0)1235 834734 or 07860 842756 Seymour Pierce (Broker)Mark Percy, Nominated Adviser +44 (0)20 7107 8032 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defence andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.